Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:
- a statement commenting on that the Senate Judiciary Committee’s “historic markup of three bipartisan, bicameral pro-patent bills” this Thursday;
- an article reporting that a bipartisan group of Representatives has recently “introduced the ‘Nurture Originals, Foster Art, and Keep Entertainment Safe Act of 2024’ (NO FAKES Act)” in the House of Representatives;
- an article highlighting 11 key patent cases to “look out for” this fall in both the Federal Circuit and the Supreme Court.
A statement from the Innovation Alliance comments on the Senate Judiciary Committee’s “historic markup of three bipartisan, bicameral pro-patent bills” this Thursday, September 19. The statement says the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act “will restore fairness to the USPTO’s Patent Trial and Appeal Board . . . process,” the Patent Eligibility Restoration Act (PERA) will “restore certainty and predictability to patent subject matter eligibility,” and the Inventor Diversity for Economic Advancement (IDEA) Act “will help us obtain the information we need to expand our innovation talent pool and compete globally.”
In an article published by IP Watchdog, Eileen McDermott reports that a bipartisan group of Representatives has recently “introduced the ‘Nurture Originals, Foster Art, and Keep Entertainment Safe Act of 2024’ (NO FAKES Act)” in the House of Representatives. McDermott notes the bill aims to “create a federal IP right to an individual’s voice and likeness” to help “curb abuse of artificial intelligence.” McDermott notes how this act is just one of “several patent bills as key pro-IP proposals that have been introduced on a bipartisan basis in both the Senate and House.”
Edward Lanquist and Wesley Barbee posted an article with Law360 highlighting 11 key patent cases to “look out for” this fall in both the Federal Circuit and the Supreme Court. The authors note how these cases span “a range of industries and interests, including biotech innovation, administrative rulemaking, and patent eligibility.” They assert the outcomes of these cases could significantly impact “the requirements for obtaining and maintaining patent protection.”